Article
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
British journal of cancer - 29 Mar 2011
Park S R, Kong S-Y, Nam B-H, Choi I J, Kim C G, Lee J Y, Cho S J, Kim Y W, Ryu K W, Lee J H, Rhee J, Park Y-I, Kim N K
Abstract excerpt
BACKGROUND: We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin. METHODS: Among MGC patients (n=108), who received S-1 (40 mg m(-2) b.i.d., days 1-14) and cisplatin (60 mg m(-2), day 1)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
